Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 1591 AL 1605

Inflammation, Dopaminergic Brain and Bilirubin

Jayanti S, Dalla Verde C, Tiribelli C, Gazzin S.

Int J Mol Sci. 2023 Jul 14;24(14):11478. doi: 10.3390/ijms241411478.

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Kong AH, Wu AJ, Ho OK, Leung MM, Huang AS, Yu Y, Zhang G, Lyu A, Li M, Cheung KH.

Int J Mol Sci. 2023 Jul 22;24(14):11780. doi: 10.3390/ijms241411780.

Naphthoquinones as a Promising Class of Compounds for Facing the Challenge of Parkinson's Disease

Santos TB, de Moraes LGC, Pacheco PAF, Dos Santos DG, Ribeiro RMAC, Moreira CDS, da Rocha DR.

Pharmaceuticals (Basel). 2023 Nov 8;16(11):1577. doi: 10.3390/ph16111577.

Fahr's disease presenting as Parkinson's disease along with dysphagia and dysarthria: A case report

Sapkota D, Neupane S, Pant P, Shrestha O, Singh P, Sapkota D.

Clin Case Rep. 2023 May 20;11(5):e7358. doi: 10.1002/ccr3.7358. eCollection 2023 May.

Gardenin A improves cognitive and motor function in A53T-α-syn mice

Hack W, Gladen-Kolarsky N, Chatterjee S, Liang Q, Maitra U, Ciesla L, Gray NE.

bioRxiv [Preprint]. 2023 Nov 1:2023.10.27.564401. doi: 10.1101/2023.10.27.564401.

Molecular Determinants of Mitochondrial Shape and Function and Their Role in Glaucoma

Khalimonchuk O, Becker DF.

Antioxid Redox Signal. 2023 May;38(13-15):896-919. doi: 10.1089/ars.2022.0124. Epub 2023 Jan 5.

Sub-second Dopamine Signals during Risky Decision-Making in Patients with Impulse Control Disorder

Liebenow B, Wilson T, Maas B, Aladnani E, Moran RJ, White J, Lohrenz T, Haq IU, Siddiqui MS, Laxton AW, Tatter SB, Montague PR, Kishida KT.

bioRxiv [Preprint]. 2023 Sep 13:2023.09.11.557178. doi: 10.1101/2023.09.11.557178.

Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective

Zhao Y, Liu X, Yang G.

Mol Neurobiol. 2023 Jun;60(6):3054-3070. doi: 10.1007/s12035-023-03257-3. Epub 2023 Feb 14.

Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease

Constantin VA, Szász JA, Dulamea AO, Valkovic P, Kulisevsky J.

Neuropsychiatr Dis Treat. 2023 Sep 14;19:1959-1972. doi: 10.2147/NDT.S422717. eCollection 2023.

Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease

Sohrabi T, Mirzaei-Behbahani B, Zadali R, Pirhaghi M, Morozova-Roche LA, Meratan AA.

J Mol Biol. 2023 Jun 15;435(12):167992. doi: 10.1016/j.jmb.2023.167992. Epub 2023 Feb 2.

Burning mouth disorder and Parkinson's disease: A scoping review of the literature

O G, Balasubramaniam R, Klasser GD.

J Oral Rehabil. 2023 Jun;50(6):488-500. doi: 10.1111/joor.13443. Epub 2023 Mar 22.

Successful implementation of technology in the management of Parkinson's disease: Barriers and facilitators

Laar A, Silva de Lima AL, Maas BR, Bloem BR, de Vries NM.

Clin Park Relat Disord. 2023 Feb 16;8:100188. doi: 10.1016/j.prdoa.2023.100188. eCollection 2023.

A review of studies on the implication of NLRP3 inflammasome for Parkinson's disease and related candidate treatment targets

Zeng N, Wang Q, Zhang C, Zhou Y, Yan J.

Neurochem Int. 2023 Nov;170:105610. doi: 10.1016/j.neuint.2023.105610. Epub 2023 Sep 11.

The link between the gut microbiome, inflammation, and Parkinson's disease

Nie S, Ge Y.

Appl Microbiol Biotechnol. 2023 Nov;107(22):6737-6749. doi: 10.1007/s00253-023-12789-6. Epub 2023 Sep 22.

Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease

Liu JS, Chen Y, Shi DD, Zhang BR, Pu JL.

Curr Neuropharmacol. 2023;21(3):536-546. doi: 10.2174/1570159X21666221229154830.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias